checkpoint inhibitors
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 21, 2023
Combined Dostarlimab, Standard of Care Improves Survival for Endometrial Cancer Patients
Adding the PD-1 checkpoint inhibitor Jemperli to carboplatin and paclitaxel improves survival in patients with ...
MAY 13, 2023
Treatments for Immunotherapy-Induced Colitis Might Affect Cancer Outcomes
Biologic agents commonly used to treat gastrointestinal problems associated with the use of immune checkpoint ...
NOVEMBER 12, 2021
Immunotherapies Being Tested Earlier in NSCLC
In the front-line treatment of NSCLC, the checkpoint inhibitor pembrolizumab improved progression-free survival ...
DECEMBER 16, 2016
Load more